Endogena Therapeutics’ candidate for geographic atrophy receives FDA clearance to enter clinic

Oct. 24, 2023

Endogena Therapeutics Inc. has received FDA clearance of its IND application for EA-2351 for geographic atrophy, an advanced form of age-related macular degeneration (AMD).

BioWorld Science Regulatory Ocular FDA IND

Today's news in brief

BioWorld

BioWorld briefs for Aug. 15, 2025.

Today's news in brief

BioWorld MedTech

BioWorld MedTech briefs for Aug. 15, 2025.

New research solves mystery of sex differences in acute kidney injury

BioWorld Science

German researchers have cracked the decades-long mystery of why males are more susceptible to acute kidney injury than females, demonstrating that estrogen has a...

Superluminal joins a $1.3B deal with series A backer Lilly

Deals and M&A

Superluminal Medicines Inc. and Eli Lilly and Co. are collaborating in a deal to develop cardiometabolic disease and obesity therapies by aiming at undisclosed G...

Merck’s MK-2214 shows potential to slow Alzheimer’s pathology

BioWorld Science

Abnormal tau aggregation is a hallmark of Alzheimer’s disease (AD) and a major contributor to neurodegeneration, synaptic dysfunction, and progressive functional...